Modular Medical Announces Conference Call to Discuss FDA Clearance of the MODD1 Insulin Pump
Modular Medical (NASDAQ:MODD) has announced a conference call and webcast on September 5, 2024, at 8:30 a.m. Eastern Time to discuss the recent FDA clearance of its MODD1 insulin pump. The company, which focuses on developing accessible and user-friendly insulin delivery systems, will also address next steps and upcoming milestones. The call will be accessible via phone and webcast, with replay options available until September 19, 2024. This announcement marks a significant milestone for Modular Medical as they prepare to launch their market expansion product, designed to be more accessible, easier to prescribe, and simpler to manage for patients.
Modular Medical (NASDAQ:MODD) ha annunciato una conferenza telefonica e un webcast il 5 settembre 2024, alle 8:30 ora orientale per discutere del recente via libera della FDA per la sua pompa d'insulina MODD1. L'azienda, che si concentra sullo sviluppo di sistemi di somministrazione dell'insulina accessibili e facili da usare, affronterà anche i prossimi passi e le tappe future. La chiamata sarà accessibile tramite telefono e webcast, con opzioni di replay disponibili fino al 19 settembre 2024. Questo annuncio segna un traguardo significativo per Modular Medical mentre si prepara a lanciare il suo prodotto per l'espansione del mercato, progettato per essere più accessibile, più facile da prescrivere e più semplice da gestire per i pazienti.
Modular Medical (NASDAQ:MODD) ha anunciado una conferencia telefónica y un webcast el 5 de septiembre de 2024, a las 8:30 a.m. hora del Este para discutir la reciente aprobación de la FDA de su bomba de insulina MODD1. La compañía, que se enfoca en desarrollar sistemas de entrega de insulina accesibles y fáciles de usar, también abordará los próximos pasos y los hitos futuros. La llamada será accesible por teléfono y webcast, con opciones de repetición disponibles hasta el 19 de septiembre de 2024. Este anuncio marca un hito significativo para Modular Medical mientras se prepara para lanzar su producto de expansión de mercado, diseñado para ser más accesible, más fácil de prescribir y más sencillo de manejar para los pacientes.
모듈러 메디컬(Modular Medical, NASDAQ:MODD)은 2024년 9월 5일, 동부 표준시로 오전 8시 30분에 최근 MODD1 인슐린 펌프에 대한 FDA의 승인을 논의하기 위해 전화 회의 및 웹캐스트를 개최한다고 발표했습니다. 접근 가능하고 사용자 친화적인 인슐린 전달 시스템 개발에 중점을 둔 이 회사는 다음 단계와 향후 이정표에 대해서도 설명할 것입니다. 이 통화는 전화와 웹캐스트를 통해 접근 가능하며, 재생 옵션은 2024년 9월 19일까지 제공됩니다. 이 발표는 모듈러 메디컬이 시장 확장을 위한 제품 출시를 준비하면서 중요한 이정표가 됩니다. 이 제품은 보다 접근 가능하고, 처방하기 쉬우며, 환자가 관리하기 간편하도록 설계되었습니다.
Modular Medical (NASDAQ:MODD) a annoncé une conférence téléphonique et un webinaire le 5 septembre 2024 à 8h30, heure de l'Est, pour discuter de la récente approbation par la FDA de sa pompe à insuline MODD1. L'entreprise, qui se concentre sur le développement de systèmes de livraison d'insuline accessibles et conviviaux, abordera également les prochaines étapes et les étapes à venir. L'appel sera accessible par téléphone et webinaire, avec des options de rediffusion disponibles jusqu'au 19 septembre 2024. Cette annonce marque une étape importante pour Modular Medical alors qu'ils se préparent à lancer leur produit d'expansion sur le marché, conçu pour être plus accessible, plus facile à prescrire et plus simple à gérer pour les patients.
Modular Medical (NASDAQ:MODD) hat eine Telefonkonferenz und ein Webcast für den 5. September 2024 um 8:30 Uhr Eastern Time angekündigt, um die recente FDA-Zulassung seiner MODD1-Insulinpumpe zu erörtern. Das Unternehmen, das sich auf die Entwicklung zugänglicher und benutzerfreundlicher Insulinabgabesysteme konzentriert, wird auch die nächsten Schritte und bevorstehenden Meilensteine ansprechen. Der Anruf wird über Telefon und Webcast zugänglich sein, mit Wiederholungsoptionen bis zum 19. September 2024. Diese Ankündigung stellt einen bedeutenden Meilenstein für Modular Medical dar, da sie sich auf die Einführung ihres Produkte zur Markterweiterung vorbereiten, das so gestaltet ist, dass es für Patienten zugänglicher, einfacher zu verschreiben und leichter zu handhaben ist.
- FDA clearance obtained for MODD1 insulin pump
- Company preparing to launch market expansion product
- MODD1 designed to be more accessible and user-friendly
- None.
SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it will hold a conference call and webcast tomorrow, Thursday, September 5, 2024, at 8:30 a.m. Eastern Time to discuss the U. S. Food and Drug Administration ("FDA") clearance of its MODD1 pump, as well as next steps and milestones.
Conference Call and Webcast Information
Date: September 5, 2024
Time: 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)
Conference Call Number: 1-888-506-0062
International Call Number: +1-973-528-0011
Passcode: 914895
Webcast: Click Here
For those unable to listen to the live Web broadcast, an archived webcast will be available on the Company's investor relations page at www.modular-medical.com. A replay of the conference call will also be available through September 19, 2024, and can be accessed by calling 1-877-481-4010 and using passcode 51238. International callers should dial 1-919-882-2331 and enter the same passcode at the prompt.
About Modular Medical
Modular Medical, Inc. (Nasdaq:MODD) is a medical device company that will launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and clinical efficacy, thereby making top quality insulin delivery both affordable and simple to learn. The Company's mission is to improve access to the highest standard of glycemic control for people with diabetes, taking it beyond "superusers" and providing diabetes care for the rest of us.
Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding MODD, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.
All trademarks mentioned herein are the property of their respective owners.
CONTACT:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com
SOURCE: Modular Medical, Inc.
View the original press release on accesswire.com
FAQ
When did Modular Medical (MODD) receive FDA clearance for its MODD1 insulin pump?
What are the key features of Modular Medical's (MODD) MODD1 insulin pump?
When and how can investors access Modular Medical's (MODD) conference call about the FDA clearance?
How long will the replay of Modular Medical's (MODD) conference call be available?
